157 related articles for article (PubMed ID: 18990079)
1. Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome.
Mestel DS; Beyer M; Möbs M; Steinhoff M; Sterry W; Assaf C
Expert Opin Biol Ther; 2008 Dec; 8(12):1929-39. PubMed ID: 18990079
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma.
Kim YH; Duvic M; Obitz E; Gniadecki R; Iversen L; Osterborg A; Whittaker S; Illidge TM; Schwarz T; Kaufmann R; Cooper K; Knudsen KM; Lisby S; Baadsgaard O; Knox SJ
Blood; 2007 Jun; 109(11):4655-62. PubMed ID: 17311990
[TBL] [Abstract][Full Text] [Related]
3. Mycosis fungoides and sezary syndrome: an update.
Kim EJ; Lin J; Junkins-Hopkins JM; Vittorio CC; Rook AH
Curr Oncol Rep; 2006 Sep; 8(5):376-86. PubMed ID: 16901399
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies against cutaneous T-cell lymphomas.
Alaibac M
Expert Opin Biol Ther; 2017 Dec; 17(12):1503-1510. PubMed ID: 28829215
[TBL] [Abstract][Full Text] [Related]
5. The Microenvironment's Role in Mycosis Fungoides and Sézary Syndrome: From Progression to Therapeutic Implications.
Pileri A; Guglielmo A; Grandi V; Violetti SA; Fanoni D; Fava P; Agostinelli C; Berti E; Quaglino P; Pimpinelli N
Cells; 2021 Oct; 10(10):. PubMed ID: 34685762
[TBL] [Abstract][Full Text] [Related]
6. Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome.
Yano H; Ishida T; Inagaki A; Ishii T; Ding J; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
Clin Cancer Res; 2007 Nov; 13(21):6494-500. PubMed ID: 17975162
[TBL] [Abstract][Full Text] [Related]
7. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
8. New aspects of the clinicopathological features and treatment of mycosis fungoides and Sézary syndrome.
Furue M; Kadono T
J Dermatol; 2015 Oct; 42(10):941-4. PubMed ID: 26432429
[TBL] [Abstract][Full Text] [Related]
9. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
10. Myocosis fungoides--an update on a non-mycotic disease.
Makdisi J; Friedman A
J Drugs Dermatol; 2013 Jul; 12(7):825-31. PubMed ID: 23884501
[TBL] [Abstract][Full Text] [Related]
11. [Anti-CCR4 monoclonal antibody as a novel therapy for advanced mycosis fungoides and Sézary syndrome].
Yano H; Ishida T; Inagaki A; Ishii T; Ri M; Ito A; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
Rinsho Ketsueki; 2009 Dec; 50(12):1671-8. PubMed ID: 20068273
[No Abstract] [Full Text] [Related]
12. Mycosis Fungoides and Sezary Syndrome.
Foss FM; Girardi M
Hematol Oncol Clin North Am; 2017 Apr; 31(2):297-315. PubMed ID: 28340880
[TBL] [Abstract][Full Text] [Related]
13. A practical approach to accurate classification and staging of mycosis fungoides and Sézary syndrome.
Thomas BR; Whittaker S
Skin Therapy Lett; 2012 Dec; 17(10):5-9. PubMed ID: 23223768
[TBL] [Abstract][Full Text] [Related]
14. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.
Trautinger F; Eder J; Assaf C; Bagot M; Cozzio A; Dummer R; Gniadecki R; Klemke CD; Ortiz-Romero PL; Papadavid E; Pimpinelli N; Quaglino P; Ranki A; Scarisbrick J; Stadler R; Väkevä L; Vermeer MH; Whittaker S; Willemze R; Knobler R
Eur J Cancer; 2017 May; 77():57-74. PubMed ID: 28365528
[TBL] [Abstract][Full Text] [Related]
15. [Quality of life of patients with mycosis fungoides and Sézary syndrome].
Jäger M; Özistanbullu D; Klemke CD; Tratzmiller S
Dermatologie (Heidelb); 2022 Oct; 73(10):759-764. PubMed ID: 36074143
[TBL] [Abstract][Full Text] [Related]
16. Circulating CD4+CD7- lymphocyte burden and rapidity of response: predictors of outcome in the treatment of Sézary syndrome and erythrodermic mycosis fungoides with extracorporeal photopheresis.
Stevens SR; Baron ED; Masten S; Cooper KD
Arch Dermatol; 2002 Oct; 138(10):1347-50. PubMed ID: 12374541
[TBL] [Abstract][Full Text] [Related]
17. Mycosis fungoides and Sézary syndrome.
Hwang ST; Janik JE; Jaffe ES; Wilson WH
Lancet; 2008 Mar; 371(9616):945-57. PubMed ID: 18342689
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic hematopoietic stem cell transplantation for refractory mycosis fungoides (MF) and Sezary syndrome (SS).
Atilla E; Atilla PA; Bozdag SC; Yuksel MK; Toprak SK; Topcuoglu P; Akay BN; Sanli H; Gurman G; Ozcan M
Int J Hematol; 2017 Sep; 106(3):426-430. PubMed ID: 28466385
[TBL] [Abstract][Full Text] [Related]
19. Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium.
Olsen EA; Hodak E; Anderson T; Carter JB; Henderson M; Cooper K; Lim HW
J Am Acad Dermatol; 2016 Jan; 74(1):27-58. PubMed ID: 26547257
[TBL] [Abstract][Full Text] [Related]
20. Mycosis fungoides and the Sézary syndrome.
Kim YH; Hoppe RT
Semin Oncol; 1999 Jun; 26(3):276-89. PubMed ID: 10375085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]